JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis
New England Journal of Medicine - United States
doi 10.1056/nejmoa1110556
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 1, 2012
Authors
Publisher
Massachusetts Medical Society